Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Medical Cannabis Program topic
No spam. Unsubscribe anytime.
CCA outlines medical cannabis safety checks, seed-to-sale tracking and sales data
Summary
CCA staff briefed the Cannabis Public Health Advisory Council on medical program safeguards including product registration, compliance testing and a seed-to-sale system; staff reported roughly $75 million in medical sales through May and noted plans to expand adverse-event tracking.
The Cannabis Control Authority told the Cannabis Public Health Advisory Council that its medical cannabis program requires vendors to register products, submit packaging and labeling for approval, and pass compliance testing before sale. "Before any medical cannabis can be sold, it has to be registered first with the CCA," a CCA representative told the council.
The presenter said the authority implemented a statewide seed-to-sale tracking system last summer that records products through cultivation, testing and dispensation and can prevent noncompliant batches from being dispensed. Staff reported cumulative medical-sales data through May of about $75,000,000 and an average of roughly $15,000,000 per month since tracking began. The CCA also described its labeling checklist (including a universal symbol and required warnings) and said testing requirements vary by product type.
Council members pressed staff for patient counts and safety data. CCA staff said registration for practitioners was removed years ago, which makes live tracking harder, but provided counts: "The number of unique patients who were dispensed cannabis in May was about 53,000," and "for all of calendar year 2025, it was 114,000, up from 104,000 in 2024." The CCA said it receives patient complaints, investigates them and intends to build more systematic adverse-event tracking as the market evolves.
The council asked CCA to continue publishing the data dashboard and to work on clearer mechanisms for collecting adverse-event reports and follow-up so regulators can identify trends as the program develops.
